In this issue:
Osteopenia associated with wasting and predictor of survival in Pancreatic adenocarcinoma
Immunotherapy in patients receiving Chemotherapy for mPDAC
Cobimetinib plus Gemcitabine use in KRAS G12R-mutated PDAC
Prognostic factors for survival in patients with mPDAC
Treatment patterns, toxicity and outcomes in older adults with advanced PDAC
Phase 2 study using neoadjuvant chemotherapy in BRPC-A
Neoadjuvant therapy vs surgery for pancreatic cancer
PARP Inhibitor with modified Folfiri vs Folfiri as second line treatment in mPDAC
Multidisciplinary team assessments of Pancreatic cancer patients
Ribociclib plus Everolimus in patients with mPDAC refractory to chemotherapy
Please login below to download this issue (PDF)